Acute Myeloid Leukemia progression In Argentinean patients with Myelodysplastic Syndromes

ENRICO, ALICIA; FLORES, GABRIELA; ARBELBIDE, JORGE; KORNBLIHTT, LAURA; CRISP, RENÉE; CORREA, WALTER A; GONZALEZ, JACQUELINE; BENGIÓ, RAQUEL; NARBAITZ, MARINA; PARDO, LAURA; WATMAN, NORA; BESTACH, YESICA; ROSENHAIN, MARIANA; BASQUIERA, ANA L; LARRIPA, IRENE; IASTREBNER, MARCELO; BELLI, CAROLINA

Vienna

Congreso; 20th Congress Of The European Hematology Association; 2015

EHA

Background: At least, one third of patients with Myelodysplastic Syndromes (MDS) develop Acute Myeloid Leukemia(AML) during the follow-up depending on diverse prognostic factors and their respective group of risk. Once the leukemicevolution occurs, the outcome of patients is very poor with short survival.Aims: To analyze prognostic variables and scoring systems regarding leukemic evolution in Argentinean population.Also, to test each category of risk trying to access differences in terms of overall survival in patients with or withoutleukemic evolution.Methods: This is a multicentric retrospective study of 966 MDS patients (532 patients belonging to the Argentinean MDSRegistry sponsored by de Argentinean Society of Hematology and the remaining to a previous multicentric study)diagnosed from 1981 to 2014. Patients were classified following FAB and WHO criteria and 59 patients presented withsecondary MDS. The median age was 66.7 (14-95) years with 74.6% above 60 years, a male/female (546/420) ratio of1.3. During the follow-up (median: 18.3 months), 424 (43.9%) died and 211 (25%) evolved to AML. BM transplantedpatients were censored till the moment of the procedure.Results: Age (limit of 60 years), percentage of bone marrow blast (0-2, 3-4, 5-9, ≥10%), hemoglobin level (